Question-and-Answer Session
Operator
(Operator Instructions) And your first question comes from the line of Ian Sanderson from Cowen & Company. Pease proceed.
Ian Sanderson - Cowen & Company
Good afternoon thanks for taking the question. And if I could ask a couple, first I don't know if this is an answerable question but if you can give us some guidance on Takeda's promotional plans for Amitiza for IBS. We are hearing from docs that there is somewhat [invisible] on that initiation and wondering if you have any visibility on when and if they plan to step that up. Related to that do you have some refill rate information for Amitiza 8 microgram just to see whether patients are staying on it and the third question is if you could just remind us what Amitiza dose is being used in the OBD Phase 3 trials. Thank you?
Stan Miele
Ian this is Stan, so I will address certainly the first part of your question as it relates to Takeda's promotional plans. As you know as stated in the contract there is a joint commercialization committee between both companies and we have routine meetings discussing a myriad of different topics as it relates to promotional plans and activities.
There is clearly a commitment on the part of Takeda to ensure that they continue to stay focused on not only the 24 microgram, but 8 microgram dosing as well for IBS-C. As I stated in the call there has been an increase of 4.5% overall. And the greatest increase of growth in total prescriptions is clearly coming from the 8 microgram dosing.
So, we will continue to have discussions with our partner about optimal measures to drive both physician response, patient request and to measure and to improve measures to drive and improved increase prescriptions. In terms of the refill rates I will have to get back to you on that.
Ian Sanderson - Cowen & Company
Okay. And then follow-up to their promotional efforts was there a contractual commitment to a spending level in the first two years post the IBS approval?
Stan Miele
Yes, there is a, I think it's stated inside, in the contract. I am not going to disclose that over the call, but I think it's very clear that 36 months post IBS-C launch it's stipulated in our contract in terms of minimal spend levels for marketing and commercialization.
Ian Sanderson - Cowen & Company
- To read the full transcript on Seeking Alpha, click here »
